Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer is a leading cause of cancer mortality globally.
• Late diagnosis and treatment resistance contribute to high mortality rates.
• Novel therapeutic strategies are urgently needed for lung cancer.

Purpose of the Study:

• To investigate the anti-cancer effects of Cediranib (CED) on non-small cell lung cancer (NSCLC) A549 cells.
• To elucidate the molecular mechanisms underlying CED's action in NSCLC.

Main Methods:

• In vitro study using NSCLC A549 cell line.
• Assessed cell proliferation, cloning formation, and cell cycle distribution.
• Analyzed protein expression related to cell cycle, apoptosis, and autophagy pathways (e.g., CDK4/cyclin D1, CDK2/cyclin E, LC3-II/LC3-I, p-Akt, p-P38, p-Erk1/2, p-mTOR).

Main Results:

• Cediranib significantly inhibited A549 cell proliferation and cloning.
• CED induced G1 phase cell cycle arrest, decreasing CDK4/cyclin D1 and CDK2/cyclin E levels.
• CED treatment increased the LC3-II/LC3-I ratio, indicating autophagy induction.
• Expression of p-Akt, p-P38, p-Erk1/2, and p-mTOR was reduced by CED.

Conclusions:

• Cediranib exhibits anti-cancer properties against NSCLC A549 cells by inducing apoptosis and G1 cell cycle arrest.
• CED may promote autophagy through the MAPK/Erk1/2 and Akt/mTOR signaling pathways in NSCLC cells.